Menu
Search
|

Menu

Close
X

Mesoblast Ltd MESO.OQ (NASDAQ Stock Exchange Global Select Market)

7.20 USD
-- (--)
As of Oct 15
chart
Previous Close 7.20
Open --
Volume --
3m Avg Volume 16,660
Today’s High --
Today’s Low --
52 Week High 8.74
52 Week Low 4.75
Shares Outstanding (mil) 96.53
Market Capitalization (mil) 728.26
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
17
FY17
2
FY16
43
FY15
35
EPS (USD)
FY18
-0.075
FY17
-0.199
FY16
-0.019
FY15
-0.512
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
42.00
6.55
Price to Book (MRQ)
vs sector
1.28
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
10.88
14.15
LT Debt to Equity (MRQ)
vs sector
10.88
11.31
Return on Investment (TTM)
vs sector
-5.48
12.83
Return on Equity (TTM)
vs sector
-6.64
14.95

EXECUTIVE LEADERSHIP

Brian Jamieson
Independent Non-Executive Chairman of the Board, Since 2007
Salary: $250,000.00
Bonus: --
Silviu Itescu
Chief Executive Officer, Executive Director, Since 2014
Salary: $1,010,000.00
Bonus: $757,500.00
William Burns
Vice Chairman of the Board, Since 2016
Salary: $167,208.00
Bonus: --
Joshua Muntner
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Peter Howard
General Counsel, Corporate Executive, Since 2011
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

L 38 55 Collins St
MELBOURNE   VIC   3000

Phone: +613.96396036

Mesoblast Limited is engaged in developing cell-based medicines. The Company has leveraged its technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic, off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

SPONSORED STORIES